Trials in Austin, Texas
Here are the top 10 medical studies for lung cancer in Austin, Texas
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
SAR408701 vs Docetaxel for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Austin, Texas
This trial is studying tusamitamab ravtansine to see how well it works compared with docetaxel in treating patients with non-small cell lung cancer that has come back or spread and express CEACAM5.
Monoclonal Antibodies
Durvalumab + Chemoradiation for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Hot Springs, Arkansas
This trial is testing whether adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab.
Tyrosine Kinase Inhibitor
Osimertinib + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
San Antonio, Texas
This trial is testing whether adding chemotherapy to osimertinib will help people with non-small cell lung cancer that has a specific DNA mutation and has gotten worse despite osimertinib.
Trials With No Placebo
Monoclonal Antibodies
Telisotuzumab Vedotin for Lung Cancer
Recruiting1 awardPhase 2
Temple, Texas
This trial tests telisotuzumab vedotin, a treatment that targets and kills cancer cells, in NSCLC patients with high c-Met levels. It aims to find the best patient group for this therapy and evaluate its safety and effectiveness. Telisotuzumab vedotin is a specialized treatment targeting c-Met-overexpressing tumor cells, and it has been evaluated in various studies for its safety and efficacy in treating advanced solid tumors, including non-small cell lung cancer.
BCL-2 Inhibitor
PF-06821497 for Small Cell Lung Cancer
Recruiting1 awardPhase 1
San Antonio, Texas
This trial is testing a new drug called PF-06821497 to see if it can help adults with certain hard-to-treat cancers. The drug is taken by mouth and is being studied alone or with other treatments to check its safety and effectiveness in stopping cancer growth.
Monoclonal Antibodies
DS-1062a for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
San Antonio, Texas
This trial tests a new drug, DS-1062a, on patients with advanced cancers who haven't been cured by other treatments. The goal is to find the safest dose and see if the drug can help treat these cancers.
Anti-metabolites
Maintenance Chemotherapy for Lung Cancer
Recruiting1 awardPhase 2
Baton Rouge, Louisiana
This trial is studying giving maintenance chemotherapy with or without local consolidation therapy to see if it works better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.